Alexander Schepart
0009-0000-3332-0180
2 papers found
Refreshing results…
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma
Missing publications? Search for publications with a matching author name.